Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up - Papp, Kim A (K Papp Clinical Research and Probity Medical Research) ; Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Ohtsuki, M. (Jichi Medical University) ; Beissert, Stefan (Department of Dermatology. University Hospital Carl Gustav Carus. TU Dresden) ; Zeng, J. (AbbVie Inc.) ; Rubant, S. (AbbVie Inc.) ; Sinvhal, R. (AbbVie Inc.) ; Zhao, Y. (AbbVie Inc.) ; Soliman, A.M. (AbbVie Inc.) ; Alperovich, G. (AbbVie Inc.) ; Leonardi, C. (Central Dermatology. Richmond Heights)